The share of patients who received IgG replacement within the respective PID diagnosis was: CVID (87%), agammaglobulinemia (87%), unclassified syndromic PID (63%), CSR/HIGM (Hyper-IgM) (58%), IgA with isolated IgG subclass deficiency (58%), unclassified antibody deficiency (56%), and isolated IgG subclass deficiency (56%). This evidence concerns the gene CD40LG and pelvic inflammatory disease.